Reportlinker Adds The Top 10 Companies in the Hospital Pharmaceutical Market in China: Growth strategies, performance and SWOT analyses
NEW YORK, Oct. 19 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
China is currently the world's second largest economy and could become the world's largest economy sometime as early as 2030. According to IMS Health data, the Chinese hospital pharmaceutical market was valued at around $26bn in 2009. Pharmaceutical companies operating in China comprise both domestic and multinational companies wherein domestic products have over 60% market share. China is one of the emerging markets most targeted by foreign players due to its increasing profitability and access to innovation. This report profiles the leading players in the Chinese hospital pharmaceutical market comprising both domestic and multinational companies. This report analyzes the hospital pharmaceutical market in China in terms of market size, key drivers and resistors, trends, and competitive positioning of major players in the market. It includes profiles of the top 10 companies in the industry and provides a brief summary of other leading players.
Introduction
This report analyzes the hospital pharmaceutical market in China in terms of market size, key drivers and resistors, trends, and competitive positioning of major players in the market. It includes profiles of the top 10 companies in the industry and provides a brief summary of other leading players. rbhc0281
Scope of this research
• Understand how recent events are affecting the performance of major companies' products.
• Gain up-to-date information across a wide range of marketed products, R&D pipelines, market share data, and competitive landscape for leading players.
• Evaluate the Chinese hospital pharmaceutical market in terms of pricing and regulation, intellectual property rights, and trends in the country.
• Compare the product franchises of top pharmaceutical players across major therapeutic areas.
• Analyze the performance of the key Chinese pharmaceutical companies.
Research and analysis highlights
The hospital pharmaceutical market in China is highly competitive and fragmented, with the top 10 players accounting for 29% of the total sales in 2009. Pfizer captured the highest market share, followed by AstraZeneca and Bayer.
Owing to improving intellectual property rights (IPR), increasing medical insurance coverage of urban and rural residents and growing consumer demand for quality healthcare in China, the Chinese pharmaceutical industry is further expected to grow in the near future.
The hurdles faced by pharmaceutical companies due to the complex drug distribution system and increasing price pressures by the Chinese authorities are resistors to growth of the pharmaceutical industry.
Key reasons to purchase this research
• What was the market size of the Chinese hospital pharmaceutical market in 2009 and what are the key trends in the market?
• Who were the top 10 players in the Chinese hospital pharmaceutical market in 2009 and what are their key therapeutic areas?
• What are the significant market and pipeline developments that may shape corporate strategies for leading drug majors in China?
• What is the structure of the drug regulatory system in China?
• Which are the key Traditional Chinese Medicines (TCMs) in the Chinese hospital pharmaceutical market?
Table of Contents
About the author 2
Disclaimer 2
Executive summary 14
Industry overview 14
Pfizer 14
AstraZeneca 15
Bayer 16
Sanofi-Aventis 16
Roche 17
Js Yangzijiang Fty 17
Merck & Co. 18
Kelun Pharmaceutical 19
Shandong Qilu 19
GlaxoSmithKline (GSK) 20
Chapter 1 Scope and methodology 21
Scope 21
Methodology 21
IMS caveat 22
Chapter 2 Industry overview 23
Summary 23
Introduction 23
Key market drivers and resistors 24
Market drivers 24
Market resistors 25
The Chinese healthcare system 26
Chinese drug approval system 28
Chinese drug regulatory system 29
Intellectual property protection 31
Pricing and reimbursement 33
Drug distribution system 35
Recent healthcare reforms and their impact on the Chinese pharmaceutical industry 37
Generics market in China 39
Biotech developments in China 41
Improving scientific base 43
Chinese biosimilar market 43
Major biosimilars in China 45
Traditional Chinese medicines (TCMs) 46
Market dynamics 47
Chinese pharmaceutical market size and growth 47
Leading therapeutic areas 48
Competitive landscape 49
Competitive positioning of the top 10 companies 49
Chapter 3 Pfizer 52
Summary 52
Company overview 53
Therapeutic area focus 54
Marketed product portfolio 55
Research and development 56
Growth strategies 58
Co-promotion of Takeda's Actos 58
Strategic partnership with BMP Sunstone to co-promote Depo-Provera 58
Pfizer's recent developments in the R&D sector 58
SWOT analysis 60
Chapter 4 AstraZeneca 61
Summary 61
Company overview 62
Therapeutic area focus 62
Marketed product portfolio 63
Research and development 64
Growth strategies 65
Establishment of API production, medicine formulation and packaging sites in China 65
R&D investments in China 66
AstraZeneca's new site in Zhangjiang, High-Tech Park 66
SWOT analysis 67
Chapter 5 Bayer 68
Summary 68
Company overview 69
Therapeutic area focus 69
Marketed product portfolio 70
Research and development 71
Growth strategies 72
Establishment of Bayer-Tsinghua Research Center 72
Partnership with the People's Liberation Army General Hospital 72
Strategic acquisitions and in-licensing of products in China 73
SWOT analysis 74
Chapter 6 Sanofi-Aventis 75
Summary 75
Company overview 76
Therapeutic area focus 76
Marketed product portfolio 77
Research and development 79
Growth strategies 81
Sanofi-Aventis's alliances and partnerships in China 81
Increasing R&D and expanding manufacturing capabilities in China 81
SWOT analysis 82
Chapter 7 Roche 83
Summary 83
Company overview 83
Therapeutic area focus 84
Marketed product portfolio 85
Research and development 86
Growth strategies 88
Extensive R&D activity at its center in Shanghai 88
Establishment of manufacturing units in China 88
SWOT analysis 89
Chapter 8 Js.Yangzijiang Fty 90
Summary 90
Company overview 91
Therapeutic area focus 91
Marketed product portfolio 92
Research and development 92
SWOT analysis 93
Chapter 9 Merck & Co. 94
Summary 94
Company overview 95
Therapeutic area focus 95
Marketed product portfolio 96
Research and development 97
Growth strategies 98
Joint venture with Sinopharm to market human papillomavirus vaccines (HPV) 98
Establishment of Merck Serono's R&D center in China 99
SWOT analysis 99
Chapter 10 Kelun group 100
Summary 100
Company overview 101
Therapeutic area focus 101
Marketed product portfolio 102
Research and development 103
SWOT analysis 104
Chapter 11 Shandong Qilu Fty 105
Summary 105
Company overview 106
Therapeutic area focus 106
Marketed product portfolio 107
Research and development 108
SWOT analysis 109
Chapter 12 GlaxoSmithKline (GSK) 110
Summary 110
Company overview 111
Therapeutic area focus 112
Marketed product portfolio 113
Research and development 114
Growth strategies 115
Joint venture with Shenzhen Neptunus to develop influenza vaccines 115
Joint venture with Jiangsu Walvax to develop pediatric vaccines 115
China to be GSK's center for global R&D in the near future 116
Drapolene launched in China 116
SWOT analysis 117
Chapter 13 11- 15 companies 118
Novartis 118
Company overview 118
Therapeutic area focus 118
Marketed products 120
Research and development 120
Js.L.Y.G. Hengrui 121
Company overview 121
Therapeutic area focus 121
Marketed products 123
Research and development 123
Hlj.Haerbin Pharmaceuticals 124
Company overview 124
Therapeutic focus 124
Marketed products 126
Research and development 126
Fresenius 127
Company overview 127
Therapeutic focus 127
Marketed products 129
Research and development 130
Novo Nordisk 130
Company overview 130
Therapeutic focus 130
Marketed products 131
Research and development 132
Appendix 133
Anatomical therapeutic chemical (ATC) classification 133
A: Alimentary tract and metabolism 133
B: Blood and blood-forming organs 133
C: Cardiovascular system 133
D: Dermatologicals 133
G: Genitourinary system and sex hormones 133
H: Systemic hormonal preparations 133
J: General anti-infectives systemic 134
K: Hospital solutions 134
L: Antineoplastic and immunomodulating agents 134
M: Musculo-skeletal system 134
N: Nervous system 134
P: Parasitology 134
R: Respiratory system 134
S: Sensory organs 135
T: Diagnostic agents 135
V: Various 135
Glossary 136
Table of figures
Figure 1: Key market drivers and resistors of Chinese pharmaceutical market 26
Figure 2: Drug approval process followed by the SFDA 28
Figure 3: Changes to the patent regime which will affect life science companies 33
Figure 4: Five-step procedure for drug pricing followed by NDRC 34
Figure 5: Drug distribution channels in China 36
Figure 6: Change in the pharmaceutical industry sector due to healthcare reforms and their
impact on key industry players 39
Figure 7: Market positioning of the top 10 companies in China, 2009 51
Figure 8: Pfizer's Chinese market sales by therapy area, 2009 55
Figure 9: Pfizer China's SWOT analysis 60
Figure 10: AstraZeneca's Chinese market sales by therapy area, 2009 63
Figure 11: AstraZeneca China's SWOT analysis 67
Figure 12: Bayer's Chinese market sales by therapy area, 2009 70
Figure 13: Bayer China's SWOT analysis 74
Figure 14: Sanofi-Aventis's Chinese market sales by therapy area, 2009 77
Figure 15: Sanofi-Aventis China's SWOT analysis 82
Figure 16: Roche's Chinese market sales by therapy area, 2009 85
Figure 17: Shanghai Roche's SWOT analysis 89
Figure 18: Js Yangzijiang Fty 's Chinese market sales by therapy area, 2009 91
Figure 19: Js Yangzijiang's SWOT analysis 93
Figure 20: Merck & Co's Chinese market sales by therapy area, 2009 96
Figure 21: Merck China's SWOT analysis 99
Figure 22: Kelun pharmaceutical's Chinese market sales by therapy area, 2009 102
Figure 23: Kelun's SWOT analysis 104
Figure 24: Shandong Qilu's Chinese market sales by therapy area, 2009 107
Figure 25: Shandong Qilu's SWOT analysis 109
Figure 26: GSK's Chinese market sales by therapy area, 2009 113
Figure 27: GSK China's SWOT analysis 117
Figure 28: Novartis's Chinese market sales by therapy area, 2009 119
Figure 29: Js.L.Y.G. Hengrui's Chinese market sales by therapy area, 2009 122
Figure 30: Hlj.Haerbin's Chinese market sales by therapy area, 2009 125
Figure 31: Fresenius' Chinese market sales by therapy area, 2009 128
Figure 32: Novo Nordisk's Chinese market sales by therapy area, 2009 131
Table of Tables
Table 1: Chinese hospital pharmaceutical market size and growth, 2009 47
Table 2: Forecast Chinese hospital pharmaceutical market size, 2009-15 48
Table 3: Chinese hospital pharmaceutical market by therapeutic segmentation, 2009 49
Table 4: Top 10 companies in Chinese hospital pharmaceutical market ($m), 2009 50
Table 5: Pfizer China Snapshot 53
Table 6: Pfizer's top 10 marketed products by sales ($m), 2009 56
Table 7: Pfizer's late-stage R&D pipeline, 2010 57
Table 8: AstraZeneca China snapshot 61
Table 9: AstraZeneca's top 10 marketed products by sales ($m), 2009 64
Table 10: AstraZeneca's late- stage R&D pipeline, 2010 (Phase III trials ongoing in China) 65
Table 11: Bayer China Snapshot 68
Table 12: Bayer's top 10 marketed products by sales ($m), 2009 71
Table 13: Bayer's late-stage R&D pipeline, 2010 72
Table 14: Sanofi-Aventis China snapshot 76
Table 15: Sanofi-Aventis's top 10 marketed products by sales ($m), 2009 78
Table 16: Sanofi-Aventis's late-stage R&D pipeline, 2010 80
Table 17: Shanghai Roche's snapshot 83
Table 18: Roche's top 10 marketed products by sales ($m), 2009 86
Table 19: Roche's late-stage R&D pipeline, 2010 87
Table 20: Js Yangzijiang Fty snapshot 90
Table 21: Js Yangzijiang's top 10 marketed products by sales ($m), 2009 92
Table 22: Merck & Co China snapshot 94
Table 23: Merck's top 10 marketed products by sales ($m), 2009 97
Table 24: Merck & Co's late-stage R&D pipeline, 2010 98
Table 25: Kelun Pharmaceutical snapshot 100
Table 26: Kelun's top 10 marketed products by sales ($m), 2009 103
Table 27: Shandong Qilu Fty snapshot 105
Table 28: Shandong Qilu's top 10 marketed products by sales ($m), 2009 108
Table 29: GSK China snapshot 111
Table 30: GSK's top 10 marketed products by sales ($m), 2009 114
Table 31: GSK China's late-stage R&D pipeline, 2010 115
Table 32: Novartis (China) snapshot 118
Table 33: Novartis's top 10 marketed products by sales ($m), 2009 120
13
Table 34: Js.L.Y.G. Hengrui snapshot 121
Table 35: Js.L.Y.G. Hengrui's top 10 marketed products by sales ($m), 2009 123
Table 36: Hlj.Haerbin Pharmaceuticals snapshot 124
Table 37: Hlj.Haerbin's top 10 marketed products by sales ($m), 2009 126
Table 38: Fresenius China snapshot 127
Table 39: Fresenius's top 10 marketed products by sales ($m), 2009 129
Table 40: Novo Nordisk China snapshot 130
Table 41: Novo Nordisk's top 10 marketed products by sales ($m), 2009 132
To order this report:
Medical Facility Industry: The Top 10 Companies in the Hospital Pharmaceutical Market in China: Growth strategies, performance and SWOT analyses
Medical Facility Business News
Check our Company Profile, SWOT and Revenue Analysis!
Contact Nicolas Bombourg |
|
Reportlinker |
|
Email: [email protected] |
|
US: (805)652-2626 |
|
Intl: +1 805-652-2626 |
|
SOURCE Reportlinker
Share this article